Results 71 to 80 of about 344,100 (302)

Choosing drugs for UK COVID-19 treatment trials

Nature Reviews Drug Discovery, 2021
In 2020, the UK government funded a portfolio of platform trials to develop new treatments for COVID-19. A key feature was the independent prioritization of candidate drugs with central coordination to prevent duplication, accelerating recruitment to deliver definitive trial results.
Chinnery, PF, Bonnet, M, Cave, A, Hofer, MP, Lamb, A, McConkey, GA, Medcalf, N, Smith, SP, Tsakok, T, Watson, R, Webster, S, You, T   +11 more
openaire   +2 more sources

Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the value of MRI outcomes as endpoints for preventive and early‐stage trials of two polyglutamine spinocerebellar ataxias (SCAs). Methods A cohort of 100 participants (23 SCA1, 63 SCA3, median Scale for the Assessment and Rating of Ataxia (SARA) score = 5, 42% preataxic, and 14 gene‐negative controls) was scanned at 3T up ...
Thiago J. R. Rezende, Emilien Petit, Young Woo Park, Sophie Tezenas du Montcel, James M. Joers, Jonathan M. DuBois, H. Moore Arnold, Michal Povazan, Ipek Özdemir, Guita Banan, Romain Valabregue, Philipp Ehses, Jennifer Faber, Chiadi U. Onyike, Peter B. Barker, Jeremy D. Schmahmann, Eva‐Maria Ratai, Sub H. Subramony, Thomas H. Mareci, Khalaf O. Bushara, Henry Paulson, Thomas Klockgether, Alexandra Durr, Tetsuo Ashizawa, Christophe Lenglet, Gülin Öz, READISCA Investigators   +26 more
wiley   +1 more source

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives

Frontiers in Pharmacology, 2020
The COVID-19 pandemic represents an unprecedented challenge for the researchers to offer safe, tolerable, and effective treatment strategies for its causative agent known as SARS-CoV-2.
Chandan Sarkar, Milon Mondal, Muhammad Torequl Islam, Muhammad Torequl Islam, Miquel Martorell, Miquel Martorell, Anca Oana Docea, Alfred Maroyi, Javad Sharifi-Rad, Daniela Calina   +9 more
doaj   +1 more source

Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS

Frontiers in Pharmacology, 2022
Acute kidney injury (AKI) is a common complication among patients with the novel coronavirus (COVID-19). COVID-19 along with AKI usually resulted in a poor prognosis for those affected.
Bin Wu, Min Luo, Fengbo Wu, Zhiyao He, Yuwen Li, Ting Xu, Ting Xu   +6 more
doaj   +1 more source

Equivalent Mid-Term Results of Open vs Endoscopic Gluteal Tendon Tear Repair Using Suture Anchors in Forty-Five Patients. [PDF]

, 2020
BackgroundLittle is known about the relative efficacy of open (OGR) vs endoscopic (EGR) gluteal tendon repair of gluteal tendon tears in minimizing pain and restoring function.
Bini, Stefano A, Jäger, Marcus, Maslaris, Alexander, Patel, Rina, Vail, Thomas P, Zhang, Alan L   +5 more
core  

Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome. [PDF]

, 2017
In the 50 years since acute respiratory distress syndrome (ARDS) was first described, substantial progress has been made in identifying the risk factors for and the pathogenic contributors to the syndrome and in characterising the protein expression ...
Calfee, Carolyn S, Meyer, Nuala J
core   +1 more source

Physician Referral Patterns to Physical Therapists for Managing Knee Osteoarthritis: A Retrospective Analysis of Electronic Health Records From an Integrated Health System

Arthritis Care &Research, EarlyView.
Objective This study aims to describe the frequency and timing of physician referrals to physical therapists (PTs) and other treatments prescribed over 12 months in patients with recent onset of knee osteoarthritis (KOA). The study also aims to identify determinants of early PT referrals.
Samannaaz S. Khoja, Joel M. Stevans, Gustavo J. Almeida, Clair Smith, Janet K. Freburger   +4 more
wiley   +1 more source

Current therapeutic approaches to haemostasis correction in covid-19: a systematic review

Кубанский научный медицинский вестник, 2021
Background. The coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus has swept across countries worldwide. Despite an unprecedented volume of research, few drug therapies have been proved effective.
V. N. Antonov, M. V. Osikov, G. L. Ignatova, S. О. Zotov   +3 more
doaj   +1 more source

Digital Orthopaedics: A Glimpse Into the Future in the Midst of a Pandemic. [PDF]

, 2020
BackgroundThe response to COVID-19 catalyzed the adoption and integration of digital health tools into the health care delivery model for musculoskeletal patients. The change, suspension, or relaxation of Medicare and federal guidelines enabled the rapid
Ast, Michael P, Bini, Stefano A, Chung, Christopher C, Kalore, Niraj V, Lawrie, Charles M, Maratt, Joseph D, Patel, Shaun P, Schilling, Peter L, Schuett, Dustin J, Steele, G Daxton   +9 more
core  

Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir

Medicina Clínica (English Edition), 2020
To determine the prevalence of potential interactions in COVID19 patients receiving lopinavir/ritonavir (LPV/r). The secondary objective was to develop recommendations and identify the risk factors associated with presenting potential interactions with LPV/r.Cross-sectional and multicenter study with the participation of 2 hospitals.
Brandariz-Nuñez, David, Correas-Sanahuja, Marcelo, Guarc, Eva, Picón, Rafael, García, Bárbara, Gil, Rocío   +5 more
openaire   +3 more sources